{"id":11495,"date":"2026-10-10T00:15:44","date_gmt":"2026-10-09T21:15:44","guid":{"rendered":"https:\/\/www.ortaakarsu.net\/?p=11495"},"modified":"2026-10-10T00:15:44","modified_gmt":"2026-10-09T21:15:44","slug":"glp-1-ozempic-mounjaro-ameliyat-anestezi","status":"publish","type":"post","link":"https:\/\/www.ortaakarsu.net\/?p=11495","title":{"rendered":"Ozempic ve Mounjaro Kullan\u0131rken Ameliyat: GLP-1 ve Anestezi Rehberi"},"content":{"rendered":"<p><strong>K\u0131sa yan\u0131t:<\/strong> Ozempic veya Mounjaro kullan\u0131yorsan\u0131z ameliyat\u0131, endoskopiyi ya da derin sedasyon gerektiren i\u015flemi planlayan ekibe bunu \u00f6nceden bildirin. G\u00fcncel yakla\u015f\u0131m b\u00fct\u00fcn hastalar\u0131n ilac\u0131n\u0131 ayn\u0131 s\u00fcreyle kesmesi de\u011fildir. Bir\u00e7ok d\u00fc\u015f\u00fck riskli hasta tedavisine devam edebilir; ancak ila\u00e7, beslenme ve anestezi plan\u0131n\u0131 anestezi uzman\u0131, i\u015flemi yapacak hekim ve tedaviyi re\u00e7eteleyen ekip birlikte belirlemelidir.<\/p>\n<h2>Mide bo\u015falmas\u0131 anesteziyi neden ilgilendirir?<\/h2>\n<p>Semaglutid i\u00e7eren Ozempic ve Wegovy gibi GLP-1 ila\u00e7lar\u0131 mide bo\u015falmas\u0131n\u0131 yava\u015flatabilir. Mounjaro&#8217;nun etken maddesi tirzepatid, hem GIP hem GLP-1 resept\u00f6rlerini etkiler ve ayn\u0131 a\u00e7\u0131dan de\u011ferlendirilir. \u0130\u015flem \u00f6ncesi a\u00e7l\u0131k talimat\u0131na uyulmas\u0131na ra\u011fmen midede i\u00e7erik kalabilir. Genel anestezi veya derin sedasyon s\u0131ras\u0131nda bu i\u00e7eri\u011fin solunum yollar\u0131na ka\u00e7mas\u0131 aspirasyon olarak adland\u0131r\u0131l\u0131r ve ciddi akci\u011fer sorunlar\u0131na neden olabilir. Risk de\u011ferlendirmesi, ilac\u0131 yaln\u0131zca kilo kontrol\u00fc i\u00e7in kullanan ki\u015filer i\u00e7in de ge\u00e7erlidir.<\/p>\n<h2>\u0130la\u00e7 otomatik olarak b\u0131rak\u0131lmal\u0131 m\u0131?<\/h2>\n<p>Hay\u0131r. ABD&#8217;deki 2024 \u00e7ok dernekli rehber, \u00e7o\u011fu hastan\u0131n devam edebilece\u011fini; y\u00fcksek riskte ek \u00f6nlemler gerekti\u011fini belirtir. ASA&#8217;n\u0131n 2025 hasta bilgilendirmesi de bu yakla\u015f\u0131m\u0131 s\u00fcrd\u00fcr\u00fcr. MHRA&#8217;n\u0131n 2025 uyar\u0131s\u0131 aspirasyon riskini vurgular ve bireysel anestezi de\u011ferlendirmesini esas al\u0131r. \u00d6zellikle diyabet i\u00e7in kullan\u0131lan ilac\u0131 plans\u0131z kesmek kan \u015fekeri kontrol\u00fcn\u00fc bozabilir. \u0130nternetteki tek bir \u201c\u015fu kadar g\u00fcn b\u0131rak\u201d kural\u0131n\u0131 uygulamay\u0131n; ba\u015fka bir hastaya verilen talimat sizin plan\u0131n\u0131z de\u011fildir.<\/p>\n<h2>Hangi durumlarda haz\u0131rl\u0131k de\u011fi\u015febilir?<\/h2>\n<p>Tedaviye yeni ba\u015flama veya doz art\u0131rma d\u00f6nemi, belirgin bulant\u0131 ve kusma, kar\u0131n a\u011fr\u0131s\u0131, kab\u0131zl\u0131k ve mide bo\u015falmas\u0131n\u0131 yava\u015flatabilen ba\u015fka hastal\u0131klar de\u011ferlendirmede \u00f6nemlidir. Doz art\u0131r\u0131m\u0131 s\u00fcrerken veya \u00f6nemli sindirim yak\u0131nmalar\u0131 varken planl\u0131 i\u015flemin ertelenmesi d\u00fc\u015f\u00fcn\u00fclebilir. Bu karar ekip taraf\u0131ndan verilir. Belirti bulunmamas\u0131 da tek ba\u015f\u0131na midenin bo\u015f oldu\u011funun garantisi de\u011fildir; i\u015flem t\u00fcr\u00fc ve ki\u015fisel \u00f6yk\u00fc birlikte de\u011ferlendirilir.<\/p>\n<h2>24 saat s\u0131v\u0131 haz\u0131rl\u0131\u011f\u0131 herkese ayn\u0131 m\u0131?<\/h2>\n<p>Uluslararas\u0131 rehberlerin ayr\u0131nt\u0131lar\u0131 farkl\u0131d\u0131r. ABD yakla\u015f\u0131m\u0131 y\u00fcksek riskte i\u015flemden \u00f6nce 24 saat yaln\u0131z s\u0131v\u0131 beslenme gibi \u00f6nlemleri de\u011ferlendirirken, Avustralya ve Yeni Zelanda&#8217;n\u0131n 2025 \u00e7ok dernekli belgesi GLP-1 kullanan t\u00fcm hastalar i\u00e7in 24 saat berrak s\u0131v\u0131 haz\u0131rl\u0131\u011f\u0131n\u0131 \u00f6nerir. Bu farkl\u0131l\u0131k, kendi ba\u015f\u0131n\u0131za bir a\u00e7l\u0131k veya s\u0131v\u0131 diyeti program\u0131 olu\u015fturman\u0131z gerekti\u011fi anlam\u0131na gelmez. Ekibiniz hangi s\u0131v\u0131lar\u0131n uygun oldu\u011funu, ne zaman kesilece\u011fini ve diyabet tedavisinin nas\u0131l y\u00f6netilece\u011fini yaz\u0131l\u0131 olarak a\u00e7\u0131klamal\u0131d\u0131r. Gerekti\u011finde mide ultrasonu veya anestezi tekni\u011finde de\u011fi\u015fiklik de\u011ferlendirilebilir.<\/p>\n<h2>\u0130\u015flem \u00f6ncesi ekibe iletilecek bilgiler<\/h2>\n<ul>\n<li>\u0130lac\u0131n tam ad\u0131, etken maddesi ve kutusu.<\/li>\n<li>Son uygulama tarihi ve mevcut re\u00e7ete bilgisi.<\/li>\n<li>Tedaviye ba\u015flang\u0131\u00e7 ve son doz art\u0131r\u0131m\u0131n\u0131n tarihi.<\/li>\n<li>Bulant\u0131, kusma, kab\u0131zl\u0131k veya kar\u0131n a\u011fr\u0131s\u0131n\u0131n varl\u0131\u011f\u0131.<\/li>\n<li>Di\u011fer diyabet ila\u00e7lar\u0131, ins\u00fclin ve b\u00fct\u00fcn takviyeler.<\/li>\n<li>Size verilen a\u00e7l\u0131k talimat\u0131 ve uygulamada ya\u015fanan g\u00fc\u00e7l\u00fckler.<\/li>\n<\/ul>\n<p>\u201cKilo i\u011fnesi oldu\u011fu i\u00e7in ila\u00e7 say\u0131lmaz\u201d diye d\u00fc\u015f\u00fcnmeyin. Endoskopi veya kolonoskopide sedasyon planlan\u0131yorsa da ayn\u0131 bilgileri payla\u015f\u0131n. Talimat\u0131 yerine getiremediyseniz veya yanl\u0131\u015fl\u0131kla yiyip i\u00e7tiyseniz durumu i\u015flem ba\u015flamadan a\u00e7\u0131klay\u0131n. Tedaviye ara verilmi\u015fse yeniden ba\u015flama plan\u0131n\u0131 da re\u00e7eteleyen ekipten \u00f6\u011frenin.<\/p>\n<h2>Acil i\u015flem ve ciddi belirtiler<\/h2>\n<p>Acil ameliyat gereksiniminde ilac\u0131n v\u00fccuttan uzakla\u015fmas\u0131n\u0131 beklemek i\u00e7in sa\u011fl\u0131k ba\u015fvurusunu ertelemeyin; son kullan\u0131m\u0131 ekibe s\u00f6yleyin. Anestezi uzman\u0131 uygun koruyucu \u00f6nlemleri belirler. Nefes almakta g\u00fc\u00e7l\u00fck, bay\u0131lma veya bilin\u00e7 bozulmas\u0131 geli\u015firse 112&#8217;yi aray\u0131n. Devam eden kusma ve belirgin kar\u0131n a\u011fr\u0131s\u0131n\u0131 da i\u015flem g\u00fcn\u00fcne kadar saklamay\u0131n; ekibi gecikmeden bilgilendirin.<\/p>\n<h2>\u0130lgili ila\u00e7 kay\u0131tlar\u0131 ve rehberler<\/h2>\n<p>A\u015fa\u011f\u0131daki kay\u0131tlar birlikte kullan\u0131m\u0131n g\u00fcvenli oldu\u011fu veya \u00fcr\u00fcnlerin birbirinin yerine ge\u00e7ebilece\u011fi anlam\u0131na gelmez.<\/p>\n<ul>\n<li><a href=\"https:\/\/www.ortaakarsu.net\/?ism_drug=ozempic-1-mg-kalem\">Ozempic 1 mg Kalem \u2014 ila\u00e7 kayd\u0131<\/a><\/li>\n<li><a href=\"https:\/\/www.ortaakarsu.net\/?ism_drug=mounjaro-5-mg-0-5-ml-kalem\">Mounjaro 5 mg\/0.5 ml Kalem \u2014 ila\u00e7 kayd\u0131<\/a><\/li>\n<li><a href=\"https:\/\/www.ortaakarsu.net\/?ism_drug=wegovy-2-4-mg-kalem\">Wegovy 2.4 mg Kalem \u2014 ila\u00e7 kayd\u0131<\/a><\/li>\n<li><a href=\"https:\/\/www.ortaakarsu.net\/?p=9657\">Ozempic Yan Etkileri ve Kilo Kayb\u0131: Zay\u0131flama \u0130\u011fnesi Hakk\u0131nda Bilmeniz Gereken 7 Ger\u00e7ek<\/a><\/li>\n<li><a href=\"https:\/\/www.ortaakarsu.net\/?p=11464\">GLP-1 \u0130la\u00e7lar\u0131 ve Tirzepatid: Kullan\u0131m Ama\u00e7lar\u0131, Etkile\u015fimler ve G\u00fcvenlik<\/a><\/li>\n<li><a href=\"https:\/\/www.ortaakarsu.net\/?p=11494\">Metformin Kullan\u0131rken B12, B\u00f6brek ve Alkol Hakk\u0131nda Bilinmesi Gerekenler<\/a><\/li>\n<\/ul>\n<p><a href=\"https:\/\/www.ortaakarsu.net\/?ism_hub=1#konu-rehberleri\">T\u00fcm konu rehberlerine ve ila\u00e7 etkile\u015fim sorgusuna d\u00f6n\u00fcn<\/a>.<\/p>\n<h2>Kaynaklar ve kontrol tarihi<\/h2>\n<p>Kaynak kontrol\u00fc: 10 Ekim 2026. A\u015fa\u011f\u0131daki resm\u00ee kurum ve \u00e7ok dernekli rehberler kar\u015f\u0131la\u015ft\u0131r\u0131lm\u0131\u015ft\u0131r. Bu sayfa ki\u015fisel anestezi plan\u0131 veya insan uzman incelemesi iddias\u0131 ta\u015f\u0131maz. Hastanenizin g\u00fcncel talimat\u0131 ve sizin i\u00e7in haz\u0131rlanan tedavi plan\u0131 esas al\u0131nmal\u0131d\u0131r.<\/p>\n<ul>\n<li><a href=\"https:\/\/www.asahq.org\/about-asa\/newsroom\/news-releases\/2024\/10\/new-multi-society-glp-1-guidance\">ASA: 2024 \u00e7ok dernekli ameliyat rehberi<\/a><\/li>\n<li><a href=\"https:\/\/madeforthismoment.asahq.org\/preparing-for-surgery\/risks\/drugs-diabetes-weight-loss\/\">ASA: 2025 hasta bilgilendirmesi<\/a><\/li>\n<li><a href=\"https:\/\/www.gov.uk\/drug-safety-update\/glp-1-and-dual-gip-slash-glp-1-receptor-agonists-potential-risk-of-pulmonary-aspiration-during-general-anaesthesia-or-deep-sedation\">MHRA: Anestezi ve aspirasyon uyar\u0131s\u0131<\/a><\/li>\n<li><a href=\"https:\/\/www.anzca.edu.au\/safety-and-advocacy\/standards-of-practice\/clinical-practice-recommendations-regarding-patients-taking-glp-1\">ANZCA: G\u00fcncel i\u015flem \u00f6ncesi \u00f6nerileri ve Nisan 2026 a\u00e7\u0131klamalar\u0131<\/a><\/li>\n<\/ul>\n<p><strong>\u0130\u00e7erik sorumlulu\u011fu:<\/strong> ortaakarsu.net i\u00e7in yapay zek\u00e2 destekli kaynak \u00f6zeti. Kaynak kontrol tarihi hekim veya eczac\u0131 taraf\u0131ndan klinik inceleme yap\u0131ld\u0131\u011f\u0131 anlam\u0131na gelmez. Ki\u015fisel tedavi \u00f6nerisi de\u011fildir; \u00fcr\u00fcn\u00fcn g\u00fcncel kullanma talimat\u0131 ve sa\u011fl\u0131k uzman\u0131n\u0131z\u0131n de\u011ferlendirmesi esas al\u0131nmal\u0131d\u0131r.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Ozempic veya Mounjaro kullan\u0131rken ameliyat \u00f6ncesi ne konu\u015fulmal\u0131? GLP-1 ve anestezi risklerini, haz\u0131rl\u0131k sorular\u0131n\u0131 ve g\u00fcncel yakla\u015f\u0131m\u0131 \u00f6\u011frenin.<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[122],"tags":[],"class_list":["post-11495","post","type-post","status-publish","format-standard","hentry","category-molekul"],"acf":[],"_links":{"self":[{"href":"https:\/\/www.ortaakarsu.net\/index.php?rest_route=\/wp\/v2\/posts\/11495","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.ortaakarsu.net\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.ortaakarsu.net\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.ortaakarsu.net\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.ortaakarsu.net\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=11495"}],"version-history":[{"count":1,"href":"https:\/\/www.ortaakarsu.net\/index.php?rest_route=\/wp\/v2\/posts\/11495\/revisions"}],"predecessor-version":[{"id":11507,"href":"https:\/\/www.ortaakarsu.net\/index.php?rest_route=\/wp\/v2\/posts\/11495\/revisions\/11507"}],"wp:attachment":[{"href":"https:\/\/www.ortaakarsu.net\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=11495"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.ortaakarsu.net\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=11495"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.ortaakarsu.net\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=11495"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}